Restorative Biosciences, Inc., researches mechanisms of tissue inflammation, performed by Professor Stephen Massia and his colleagues in the Harrington Department of Bioengineering at Arizona State University, led to the founding of Restorative Biosciences Incorporated in 2004. The company's core technology involves chemically linking bioactive ICAM-1 binding peptides to hydrophilic polymers. The resulting bioconjugates are highly effective and unique in their mechanism of action. They are the only pharmaceutical formulation known to directly disrupt immune cell adhesion onto inflamed tissue, a process central to the destructive progression of inflammation. Their lead bioconjugate compound has been accepted for veterinary use in the United States. Preparations are in progress to begin clinical trials to win approval for an indication for the treatment of Dry Eye (keratoconjunctivitis sicca), an estimated $500 million market opportunity.